Abstract
Background: It remains uncertain whether or not statin use is associated with development of micturition disorders. To examine the association between statin use and the risk of storage lower urinary tract symptoms (LUTS), data mining was performed on a claims database. Methods: Symmetry analysis was carried out to identify the risk of storage LUTS after statin use during the period from January 2005 to December 2011. Statin use in combination with drugs for storage LUTS was examined by prescription sequence symmetry analysis. Likewise, event sequence symmetry analysis was undertaken to evaluate the association between statin use and the diagnosis of storage LUTS and overactive bladder (OAB). Results: Significant associations of statin use with drugs for storage LUTS were found, with an adjusted sequence ratio (ASR) of 1.58 (1.08-2.33) at an interval of 6 months. In the analysis of drugs for OAB alone, significant associations were found, with ASRs of 1.82 (1.14-2.97) and 1.47 (1.06-2.04) at intervals of 6 and 12 months, respectively.In analyses of individual statins and drugs for OAB, a significant association was found for pravastatin, with an ASR of 2.66 (1.15-6.88) at an interval of 6 months, but not for other statins. Significant associations were found for statin users in analyses of diagnosis of OAB, with ASRs of 2.00 (1.18-3.50) and 1.58 (1.10-2.28) at intervals of 6 and 12 months. Conclusion: Analysis of the claims database demonstrated that statins might be associated with a new onset of storage LUTS. Statin-associated storage LUTS should be monitored closely in clinical practice, and further studies are needed to confirm our findings and elucidate the mechanism for statin-associated storage LUTS.
Highlights
HMG-CoA reductase inhibitors are the most commonly prescribed cardiovascular drugs worldwide
In analyses of individual statins and drugs approved for overactive bladder (OAB), a significant association was found for pravastatin, with an adjusted sequence ratio (ASR) of 2.66 (1.15-6.88) at an interval of 6 months, but not for other statins (Table 4)
Analysis of the claims database demonstrated that statin therapy might be associated with a new onset of storage lower urinary tract symptoms (LUTS)
Summary
HMG-CoA reductase inhibitors (statins) are the most commonly prescribed cardiovascular drugs worldwide. The MHRA Public Assessment Report evaluated the use of statins and the association between micturition disorders and problems with urination (micturition disorders, pollakiuria, nocturia, dysuria, micturition urgency, urinary retention, urinary incontinence, and oliguria) [3]. The MHRA Public Assessment Report concluded that it was not considered necessary to list micturition disorder in the product information for the statins other than pravastatin, as the evidence for an association of micturition disorders with their use was weak [3]. It remains uncertain whether or not statin use is associated with development of micturition disorders. To examine the association between statin use and the risk of storage lower urinary tract symptoms (LUTS), data mining was performed on a claims database
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
